Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25832100 | 0.84 | GABRG2 (0.41) | KDM4EKMT2AALDH1A1 | |
| SCHEMBL25832104 | 0.81 | AR (0.37) | CFTRKDM4EKMT2ACNR1CNR2 | |
| SCHEMBL25832098 | 0.74 | AHR (0.33) | KMT2A | |
| SCHEMBL25832251 | 0.73 | AR (0.41) | CFTRKDM4EMAPK8ALDH1A1LMNA | |
| SCHEMBL21359904 | 0.73 | CYP2B6 (0.40) | CFTRKDM4EKMT2ACNR1CNR2 | |
| SCHEMBL25832356 | 0.73 | PLA2G2A (0.36) | CFTRCNR1CNR2MAPK8LMNA | |
| SCHEMBL25832127 | 0.73 | AR (0.40) | CFTRKDM4EMAPK8ALDH1A1LMNA | |
| SCHEMBL25832402 | 0.71 | PLA2G2A (0.36) | CFTRKDM4ESMN1; SMN2MAPK8ALDH1A1 | |
| SCHEMBL24357127 | 0.71 | MAPK8 (0.37) | CFTRKDM4EKMT2AP2RX7SMN1; SMN2 | |
| SCHEMBL21358633 | 0.70 | CYP2B6 (0.49) | CFTRKDM4EKMT2ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | HAVCR2, HPD, CYP24A1 | CFTR 3135/4885KDM4E 1165/4885KMT2A 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.